The US is the bigger Biosimilars market: $15.5 Bn against $3 Bn in 2023, about 5.3 times as large.
Canada grows faster: 24.9% a year, against 22.9%. The gap still grows from $12.5 Bn to $94.6 Bn by 2033.
| Measure |  US |  Canada |
|---|---|---|
| Market size, 2023 | $15.5 Bn | $3 Bn |
| Market size, 2033 projected | $121.8 Bn | $27.3 Bn |
| Growth a year (CAGR) | 22.9% | 24.9% |
| Money added, 2023–2033 | $106.3 Bn | $24.3 Bn |
| Share of the world market | 42% | 8% |
| Size rank of 24 countries | #1 | #3 |
| Market per person, 2023 | $45 | $71 |
| Full report | US report | Canada report |
Year by year, 2023 to 2033
2023
2024
2025
2026
2027
2028
2029
2030
2031
2032
2033
US Canada · values between 2023 and 2033 are projected from the 2023 size and the CAGR.
Quick answers
Which is bigger in Biosimilars, US or Canada?
The US is the bigger Biosimilars market: $15.5 Bn against $3 Bn in 2023, about 5.3 times as large.
Which grows faster in Biosimilars, US or Canada?
Canada grows faster: 24.9% a year, against 22.9%. The gap still grows from $12.5 Bn to $94.6 Bn by 2033.
More Biosimilars comparisons
Sources: market size and growth: Acuitas Health Analytics research (2023 base year, forecasts to 2033). Trials: ClinicalTrials.gov; found by search words, so counts are a guide. Population: World Bank.